
Molecules p. 5898 - 5912 (2014)
Update date:2022-08-02
Topics:
Oliveira, Claudio B. S.
Meurer, Ywlliane S. R.
Oliveira, Marianne G.
Medeiros, Wendy M. T. Q.
Silva, Francisco O. N.
Brito, Ana C. F.
De Pontes, Daniel L.
Andrade-Neto, Valter F.
A resorcinarene derivative of vanillin, resvan, was synthesized and characterized by spectroscopic techniques. We measured the cytotoxicity (in vivo and in vitro), antioxidant and anti-Toxoplasma activities of vanillin and the resorcinarene compound. Here we show that vanillin has a dose-dependent behavior with IC50 of 645 μg/mL through an in vitro cytotoxicity assay. However, we could not observe any cytotoxic response at higher concentrations of resvan (IC50 > 2,000 μg/mL). The in vivo acute toxicity assays of vanillin and resvan exhibited a significant safety margin indicated by a lack of systemic and behavioral toxicity up to 300 mg/kg during the first 30 min, 24 h or 14 days after administration. The obtained derivative showed greater antioxidative activity (84.9%) when comparing to vanillin (19.4%) at 1,000 μg/mL. In addition, vanillin presents anti-Toxoplasma activity, while resvan does not show that feature. Our findings suggest that this particular derivative has an efficient antioxidant activity and a negligible cytotoxic effect, making it a potential target for further biological investigations.
Jinhua Haoyuan Chemical CO., LTD(expird)
Contact:86-579-82465583
Address:Jinhua,Zhejiang
Shijiazhuang Haitian Amino Acid Co., Ltd.
Contact:+86-311-88908111
Address:Shijiazhuang Hebei province,China
Nanjing Raise Pharmatech Co., Ltd
website:http://www.raisechem.com
Contact:+86-25-58649566
Address:B381,No.606,Ningliu Road,Jiangbei New Area,Nanjing,Jiangsu Province,China
JIANGSU GRAND XINYI PHARMACEUTICAL CO.,LTD
website:http://www.xypharm.com/
Contact:+86-515-84383317
Address:Chenli Road,Costal Chemical Area Binhai,Yancheng, Jiangsu,China
website:http://www.ringchemicals.com/
Contact:+1-416-493-6870
Address:Toronto, Canada
Doi:10.1055/s-0030-1259545
(2011)Doi:10.1007/s00044-015-1474-x
(2016)Doi:10.1021/jo5005394
(2014)Doi:10.1246/cl.2012.420
(2012)Doi:10.1021/ol2012204
(2011)Doi:10.1016/j.bmcl.2010.11.103
(2011)